Skip to main content

Dyne Therapeutics, Inc.

DYN
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001818794

In the last 90 days, Dyne Therapeutics, Inc. insiders filed 0 open-market purchases and 10 sales; 245 institutions reported holding it in 13F filings for Q2 2026, worth $4.23B in total; no superinvestor holds it.

Open-market trades, last 90 days

Open-market purchases (P) and sales (S) by Dyne Therapeutics, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.

Open-market buys
0 filings
Open-market sells
10 filings
6 insiders, $90.2M in total
Insiders trading
6
Net value
−$90.2M
Purchases minus sales

Insider roster

Directors, officers and 10% owners who have filed a Form 4 for Dyne Therapeutics, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.

Insider roster for Dyne Therapeutics, Inc.
NameTitleLast reported holdingLast filingFilings, past year
Friedl-Naderer JohannaChief Commercial Officer152,897Sep 8, 20267
Kerr DouglasChief Medical Officer162,564Sep 8, 20267
Cox JohnCEO & President357,507Sep 8, 20267
Rhodes Jason PDirector428,946IndirectAug 17, 20269
Lucera ErickChief Financial Officer119,766Aug 17, 20265
Kersten DirkDirector3,586,796IndirectJul 29, 20269
Greene Barry EDirector–Jun 23, 20261
Hurwitz EdwardDirector–Jun 9, 20261
Posner Brian SDirector24,500Jun 9, 20268
Lubner David CharlesDirector0Jun 9, 20262
Stehman-Breen CatherineDirector–Jun 9, 20261
Incerti CarloDirector0Jun 9, 20261
Karnani VikramDirector–Dec 23, 20251
Scalzo Richard WilliamSVP, Head of Finance & Admin.122,330Mar 13, 20250
Beskrovnaya OxanaChief Scientific Officer195,840Mar 13, 20250
High Susanna GattiChief Operating Officer131,636Sep 19, 20240
McNeill JonathanChief Business Officer132,106Aug 20, 20240
Farwell WildonChief Medical Officer143,222Aug 20, 20240
Brumm Joshua TCEO & President537,998Mar 12, 20240
Atlas Venture Opportunity Fund I, L.P.10% Owner847,388IndirectMar 5, 20240
Atlas Venture Associates Opportunity I, L.P.10% Owner847,388IndirectMar 5, 20240
Atlas Venture Associates Opportunity I, LLC10% Owner847,388IndirectMar 5, 20240
Atlas Venture Opportunity Fund II, L.P.10% Owner847,388IndirectMar 5, 20240
Atlas Venture Associates Opportunity II, LLC10% Owner847,388IndirectMar 5, 20240
Atlas Venture Associates Opportunity II, LP10% Owner847,388IndirectMar 5, 20240
Atlas Venture Fund XI, L.P.10% Owner864,487IndirectFeb 28, 20240
Atlas Venture Associates XI, LLC10% Owner864,487IndirectFeb 28, 20240
Atlas Venture Associates XI, L.P.10% Owner864,487IndirectFeb 28, 20240
Klein Lawrence OttoDirector–Jul 6, 20220

Insider trades

Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Dec 12, 2023 (view filing)Dec 11-121 dayFarwell WildonChief Medical OfficerSSale−2.67K$10.66−$28.4K−1.6%169.1K after2 lots10b5-1
Dec 12, 2023 (view filing)Dec 111 dayHigh Susanna GattiChief Operating OfficerSSale−1.62K$10.72−$17.3K−0.9%187.9K after
Dec 12, 2023 (view filing)Dec 111 dayMcNeill JonathanChief Business OfficerSSale−1.25K$10.72−$13.3K−0.8%155.5K after
Dec 12, 2023 (view filing)Dec 111 dayScalzo Richard WilliamSee RemarksSSale−1.38K$10.72−$14.8K−1.1%126.6K after
Dec 14, 2023 (view filing)Dec 14Same dayScalzo Richard WilliamSee RemarksSSale−2.38K$12.02−$28.6K−1.9%124.2K after10b5-1
Jan 4, 2024 (view filing)Jan 31 dayScalzo Richard WilliamSVP, Head of Finance & Admin.SSale−13.0K$18.81−$244.5K−9.5%124.2K after10b5-1
Jan 4, 2024 (view filing)Jan 2-42 daysMcNeill JonathanChief Business OfficerSSale−31.9K$16.59−$529.2K−18.2%143.6K after4 lots10b5-1
Jan 4, 2024 (view filing)Jan 3-41 dayBeskrovnaya OxanaChief Scientific OfficerSSale−87.8K$18.57−$1.63M−35.9%156.8K after4 lots10b5-1
Jan 4, 2024 (view filing)Jan 3-41 dayBrumm Joshua TCEO & PresidentSSale−269.7K$18.66−$5.03M−31.6%585.0K after5 lots10b5-1
Jan 11, 2024 (view filing)Jan 92 daysKersten DirkDirector, 10% OwnerPPurchase+1.71M$17.50+$30.0MNew position1.43M after2 lots
Jan 26, 2024 (view filing)Jan 26Same dayScalzo Richard WilliamSVP, Head of Finance & Admin.SSale−13.0K$24.34−$316.4K−9.5%124.2K after10b5-1
Jan 26, 2024 (view filing)Jan 26Same dayMcNeill JonathanChief Business OfficerSSale−20.0K$24.53−$490.5K−12.2%143.6K after2 lots10b5-1
Jan 26, 2024 (view filing)Jan 26Same dayFarwell WildonChief Medical OfficerSSale−100$25.00−$2.50K−0.1%169.0K after10b5-1
Feb 14, 2024 (view filing)Feb 122 daysFarwell WildonChief Medical OfficerSSale−5.49K$25.07−$137.7K−3.3%163.5K after10b5-1
Feb 20, 2024 (view filing)Feb 15-205 daysRhodes Jason PDirectorSSale−510.2K$23.26−$11.9M−7.0%6.82M after5 lots10b5-1
Feb 20, 2024 (view filing)6:35 PM ETFeb 15-205 daysAtlas Venture Fund XI, L.P. and 2 others10% OwnerSSale−510.2K$23.26−$11.9M−7.0%6.82M after5 lots10b5-1Duplicate filing
Feb 23, 2024 (view filing)Feb 21-232 daysRhodes Jason PDirectorSSale−500.8K$22.64−$11.3M−35.2%920.8K after6 lots10b5-1
Feb 23, 2024 (view filing)6:58 PM ETFeb 21-232 daysAtlas Venture Fund XI, L.P. and 8 others10% OwnerSSale−463.4K$22.64−$10.5M−6.8%6.35M after4 lots10b5-1
Feb 23, 2024 (view filing)6:58 PM ETFeb 23Same dayAtlas Venture Fund XI, L.P. and 8 others10% OwnerSSale−37.4K$22.70−$848.7K−3.9%920.8K after2 lots10b5-1
Feb 28, 2024 (view filing)Feb 28Same dayFarwell WildonChief Medical OfficerSSale−407$25.00−$10.2K−0.2%163.1K after10b5-1
Feb 28, 2024 (view filing)Feb 26-282 daysRhodes Jason PDirectorSSale−807.8K$24.30−$19.6M−48.3%864.5K after18 lots10b5-1
Feb 28, 2024 (view filing)7:13 PM ETFeb 26-282 daysAtlas Venture Fund XI, L.P. and 8 others10% OwnerSSale−654.5K$24.30−$15.9M−10.3%5.70M after6 lots10b5-1
Feb 28, 2024 (view filing)7:13 PM ETFeb 26-282 daysAtlas Venture Fund XI, L.P. and 8 others10% OwnerSSale−153.4K$24.30−$3.73M−15.1%864.5K after12 lots10b5-1
Mar 1, 2024 (view filing)Feb 29-Mar 11 dayScalzo Richard WilliamSVP, Head of Finance & Admin.SSale−12.7K$28.05−$357.3K−9.3%124.2K after3 lots10b5-1
Mar 1, 2024 (view filing)Feb 29-Mar 11 dayMcNeill JonathanChief Business OfficerSSale−28.5K$28.46−$811.9K−16.6%143.6K after4 lots10b5-1
Mar 1, 2024 (view filing)Feb 29-Mar 11 dayBrumm Joshua TCEO & PresidentSSale−100.0K$28.96−$2.90M−15.1%563.5K after4 lots10b5-1
Mar 5, 2024 (view filing)Mar 14 daysRhodes Jason PDirectorSSale−46.5K$30.05−$1.40M−5.2%847.4K after2 lots10b5-1
Mar 5, 2024 (view filing)5:07 PM ETMar 14 daysAtlas Venture Opportunity Fund I, L.P. and 5 others10% OwnerSSale−29.4K$30.05−$884.5K−2.0%1.46M after10b5-1
Mar 5, 2024 (view filing)5:07 PM ETMar 14 daysAtlas Venture Opportunity Fund I, L.P. and 5 others10% OwnerSSale−17.1K$30.05−$513.8K−2.0%847.4K after10b5-1
Mar 11, 2024 (view filing)Mar 74 daysScalzo Richard WilliamSVP, Head of Finance & Admin.SSale−2.27K$25.85−$58.8K−1.8%122.0K after10b5-1
Mar 11, 2024 (view filing)Mar 74 daysMcNeill JonathanChief Business OfficerSSale−2.43K$25.85−$62.9K−1.7%141.2K after10b5-1
Mar 11, 2024 (view filing)Mar 74 daysFarwell WildonChief Medical OfficerSSale−9.92K$25.86−$256.6K−6.1%153.2K after2 lots10b5-1
Mar 11, 2024 (view filing)Mar 74 daysHigh Susanna GattiChief Operating OfficerSSale−1.59K$25.85−$41.1K−0.8%186.3K after10b5-1
Mar 11, 2024 (view filing)Mar 74 daysBeskrovnaya OxanaChief Scientific OfficerSSale−2.37K$25.85−$61.3K−1.5%154.4K after10b5-1
Mar 11, 2024 (view filing)Mar 74 daysBrumm Joshua TCEO & PresidentSSale−9.09K$25.85−$234.9K−1.6%554.4K after10b5-1
Mar 12, 2024 (view filing)Mar 111 dayBeskrovnaya OxanaChief Scientific OfficerSSale−2.08K$25.70−$53.5K−1.3%152.4K after10b5-1
Mar 12, 2024 (view filing)Mar 8-114 daysBrumm Joshua TCEO & PresidentSSale−429.7K$25.89−$11.1M−44.4%538.0K after7 lots10b5-1
Mar 12, 2024 (view filing)Mar 8-114 daysScalzo Richard WilliamSVP, Head of Finance & Admin.SSale−88.9K$26.19−$2.33M−42.7%119.3K after5 lots10b5-1
Mar 12, 2024 (view filing)Mar 11-121 dayFarwell WildonChief Medical OfficerSSale−2.62K$25.65−$67.1K−1.7%150.6K after2 lots10b5-1
Mar 13, 2024 (view filing)Mar 8-115 daysLateHigh Susanna GattiChief Operating OfficerSSale−29.5K$26.59−$784.2K−15.8%156.8K after3 lots10b5-1
Mar 13, 2024 (view filing)6:04 AM ETMar 8-115 daysLateMcNeill JonathanChief Business OfficerSSale−109.6K$26.11−$2.86M−44.0%139.4K after5 lots10b5-1
May 17, 2024 (view filing)May 161 dayMcNeill JonathanChief Business OfficerSSale−2.77K$28.27−$78.4K−2.0%136.6K after2 lots10b5-1
May 17, 2024 (view filing)May 161 dayScalzo Richard WilliamSVP, Head of Finance & Admin.SSale−2.59K$28.27−$73.2K−2.2%116.7K after2 lots10b5-1
May 17, 2024 (view filing)May 161 dayHigh Susanna GattiChief Operating OfficerSSale−2.74K$28.27−$77.4K−1.7%154.1K after2 lots10b5-1
May 17, 2024 (view filing)May 161 dayFarwell WildonChief Medical OfficerSSale−2.38K$28.27−$67.3K−1.6%148.2K after2 lots10b5-1
May 17, 2024 (view filing)May 161 dayBeskrovnaya OxanaChief Scientific OfficerSSale−2.71K$28.27−$76.5K−1.8%149.6K after2 lots10b5-1
May 22, 2024 (view filing)May 202 daysBeskrovnaya OxanaChief Scientific OfficerSSale−30.4K$32.96−$1.00M−16.9%149.6K after3 lots10b5-1
Jun 11, 2024 (view filing)Jun 10-111 dayScalzo Richard WilliamSVP, Head of Finance & Admin.SSale−2.92K$30.74−$89.8K−2.5%113.8K after2 lots10b5-1
Jun 11, 2024 (view filing)Jun 11Same dayMcNeill JonathanChief Business OfficerSSale−1.82K$31.34−$57.1K−1.3%134.8K after
Jun 11, 2024 (view filing)Jun 10-111 dayHigh Susanna GattiChief Operating OfficerSSale−85.3K$30.30−$2.58M−36.4%148.8K after3 lots10b5-1